HOWL: Werewolf Therapeutics, Inc. Stock

by  •  • Comments Off on HOWL: Werewolf Therapeutics, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 38.01
Enterprise Value ($M) -46.89
Book Value ($M) 73.39
Book Value / Share 1.64
Price / Book 0.52
NCAV ($M) 59.53
NCAV / Share 1.33
Price / NCAV 0.64

Profitability (mra)
Return on Invested Capital (ROIC) -0.64
Return on Assets (ROA) -0.40
Return on Equity (ROE) -0.60

Liquidity (mrq)
Quick Ratio 7.45
Current Ratio 7.45

Balance Sheet (mrq) ($M)
Current Assets 113.07
Assets 126.93
Liabilities 53.54
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 1.89
Operating Income -73.59
Net Income -70.52

Cash Flow Statement (mra) ($M)
Cash From Operations -56.19
Cash from Investing -0.25
Cash from Financing 13.08

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-14 13G/A PFM Health Sciences, LP 6.50
11-14 13G/A Bank Of America Corp /de/ 4.90 2.93
11-13 13G/A Rubric Capital Management LP 3.05 -31.08
11-12 13G/A Adage Capital Management, L.P. 4.58
05-07 13D/A Ra Capital Management, L.p. 14.20 0.22

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-03-11 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K
2024-11-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q
2024-08-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q
2024-05-03 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-04-17 42,546 155,476 27.36
2025-04-16 47,742 150,821 31.65
2025-04-15 66,600 327,941 20.31
2025-04-14 43,139 123,936 34.81

(click for more detail)

Similar Companies
GOSS – Gossamer Bio, Inc. HALO – Halozyme Therapeutics, Inc.
HLVX – HilleVax, Inc. HUMA – Humacyte, Inc.
IBRX – ImmunityBio, Inc.


Financial data and stock pages provided by
Fintel.io